Raymond James analyst Lawrence Keusch maintained a Buy rating on Hill-Rom (NYSE:HRC) Holdings Inc on Monday, setting a price target of $100, which is approximately 11.78% above the present share price of $89.46.
Keusch expects Hill-Rom Holdings Inc to post earnings per share (EPS) of $1.41 for the fourth quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Hill-Rom, with an average price target of $113.67.
The analysts price targets range from a high of $125 to a low of $100.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $767.5 million and a net profit of $144.8 million. The company's market cap is $5.96 billion.
According to TipRanks.com, Raymond James analyst Lawrence Keusch is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 6.2% and a 61.70% success rate.
Hill-Rom Holdings, Inc. is a medical technology company, which focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following business segments: Patient Support System, Front Line Care, and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility, and clinical workflow solutions. The Front Line Care segment offers respiratory care products; and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products, and accessories. The company was founded by William A. Hillenbrand (NYSE:HI) on August 7, 1969 and is headquartered in Chicago, IL.